U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C39H62N6O6S
Molecular Weight 743.011
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PF-06380101

SMILES

[H][C@]([C@@H](C)CC)([C@@H](CC(=O)N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(=O)N[C@@H](CC2=CC=CC=C2)C3=NC=CS3)OC)N(C)C(=O)[C@@H](NC(=O)C(C)(C)N)C(C)C

InChI

InChIKey=QAAFNSMAIAVCHE-BZLYQNAUSA-N
InChI=1S/C39H62N6O6S/c1-11-25(4)33(44(8)37(48)32(24(2)3)43-38(49)39(6,7)40)30(50-9)23-31(46)45-20-15-18-29(45)34(51-10)26(5)35(47)42-28(36-41-19-21-52-36)22-27-16-13-12-14-17-27/h12-14,16-17,19,21,24-26,28-30,32-34H,11,15,18,20,22-23,40H2,1-10H3,(H,42,47)(H,43,49)/t25-,26+,28-,29-,30+,32-,33-,34+/m0/s1

HIDE SMILES / InChI
Molecular Formula C39H62N6O6S
Molecular Weight 743.011
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

PF-06380101 is a novel cytotoxic Dolastatin 10 analogue; with excellent potencies in tumor cell proliferation assays and differential ADME properties when compared to other synthetic auristatin analogues that are used in the preparation of ADCs.

Originator

Pfizer
420
Curator's Comment: # Pfizer

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
BT-474
1
Target ID: CHEMBL614529
Inhibitor
8297
Inhibitor
8297
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Preclinical
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications.
2014 Dec 26
RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models.
2016 Nov
Quantitative Conjugated Payload Measurement Using Enzymatic Release of Antibody-Drug Conjugate with Cleavable Linker.
2017 Feb 15
Patents

Patents

US2013323234
1
US2014127211
1
US2014363452
1
US2015125472
1
US8828401
1

Sample Use Guides

In Vivo Use Guide
Rats: After an IV dose of 20a at 20 ug/kg to Wistar Han rats, PF-06380101 exhibited a mean systemic clearance (Cl) of 70 mL/min/kg and a volume of distribution (Vss) of 14.70 L/kg, resulting in a terminal elimination half-life (t1/2) of approximately 6 h.
Route of Administration: Intravenous
In Vitro Use Guide
PF-06380101 inhibited BT474 viability with GI 0.26 nM
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:22:55 GMT 2023
Edited
by admin
on Sat Dec 16 08:22:55 GMT 2023
Record UNII
Q8020AX34E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PF-06380101
Code English
(2S)-2-((2-AMINO-2-METHYL-PROPANOYL)AMINO)-N-((1S,2R)-2-METHOXY-4-((2S)-2-((1R,2R)-1-METHOXY-2-METHYL-3-OXO-3-(((1S)-2-PHENYL-1-THIAZOL-2-YL-ETHYL)AMINO)PROPYL)PYRROLIDIN-1-YL)-1-((1S)-1-METHYLPROPYL)-4-OXO-BUTYL)-N,3-DIMETHYL-BUTANAMIDE
Systematic Name English
AUR-0101
Code English
AURISTATIN 0101
Common Name English
L-VALINAMIDE, 2-METHYLALANYL-N-((1S,2R)-2-METHOXY-4-((2S)-2-((1R,2R)-1-METHOXY-2-METHYL-3-OXO-3-(((1S)-2-PHENYL-1-(2-THIAZOLYL)ETHYL)AMINO)PROPYL)-1-PYRROLIDINYL)-1-((1S)-1-METHYLPROPYL)-4-OXOBUTYL)-N-METHYL-
Systematic Name English
Code System Code Type Description
PUBCHEM
71569947
Created by admin on Sat Dec 16 08:22:55 GMT 2023 , Edited by admin on Sat Dec 16 08:22:55 GMT 2023
PRIMARY
FDA UNII
Q8020AX34E
Created by admin on Sat Dec 16 08:22:55 GMT 2023 , Edited by admin on Sat Dec 16 08:22:55 GMT 2023
PRIMARY
CAS
1436391-86-4
Created by admin on Sat Dec 16 08:22:55 GMT 2023 , Edited by admin on Sat Dec 16 08:22:55 GMT 2023
PRIMARY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966